Health TidingsImmunityBio Expands ANKTIVA Patent Protection in NMIBC Through 2035 ImmunityBio Expands ANKTIVA Patent Protection in NMIBC Through 2035 Read Post »
Health TidingsFDA Prioritizes Review of Bayer’s Sevabertinib for HER2-Mutant NSCLC FDA Prioritizes Review of Bayer’s Sevabertinib for HER2-Mutant NSCLC Read Post »
Health TidingsApnimed’s AD109 Shows Sustained Sleep Apnea Improvements Through 26 Weeks Apnimed’s AD109 Shows Sustained Sleep Apnea Improvements Through 26 Weeks Read Post »
New Drug ApprovalJapan Expands GSK’s Arexvy Approval to At-Risk Adults Aged 18–49 Japan Expands GSK’s Arexvy Approval to At-Risk Adults Aged 18–49 Read Post »
Health TidingsFDA Accepts Viatris NDA for Fast-Acting Meloxicam in Acute Pain FDA Accepts Viatris NDA for Fast-Acting Meloxicam in Acute Pain Read Post »
Clinical TrialsMerck’s Sac-TMT Shows Survival Benefit in Advanced Endometrial Cancer Merck’s Sac-TMT Shows Survival Benefit in Advanced Endometrial Cancer Read Post »
New Drug ApprovalBoehringer Ingelheim Secures Japan Approval for JASCAYD in Pulmonary Fibros... Boehringer Ingelheim Secures Japan Approval for JASCAYD in Pulmonary Fibros... Read Post »
Mergers & AcquisitionsRegeneron and Parabilis Partner to Develop Antibody-Helicon Conjugates Regeneron and Parabilis Partner to Develop Antibody-Helicon Conjugates Read Post »
ResearchTeva Highlights the Unseen Psychological Toll of Tardive Dyskinesia Teva Highlights the Unseen Psychological Toll of Tardive Dyskinesia Read Post »
New Drug ApprovalFDA Approves AstraZeneca’s Baxfendy, an Aldosterone-Targeting Therapy... FDA Approves AstraZeneca’s Baxfendy, an Aldosterone-Targeting Therapy... Read Post »
Clinical TrialsRalinepag Improved Outcomes in Phase III Pulmonary Hypertension Study Ralinepag Improved Outcomes in Phase III Pulmonary Hypertension Study Read Post »
Health Tidings Mergers & AcquisitionsImmunityBio Secures Exclusive U.S. Rights to Tokyo-172 BCG for Bladder Canc... ImmunityBio Secures Exclusive U.S. Rights to Tokyo-172 BCG for Bladder Canc... Read Post »
Clinical TrialsNovartis Shows Improved PSA Responses With Pluvicto in Phase III mHSPC Tria... Novartis Shows Improved PSA Responses With Pluvicto in Phase III mHSPC Tria... Read Post »
Clinical TrialsFDA Clears United Therapeutics’ UHeart Trial in End-Stage Heart Failure FDA Clears United Therapeutics’ UHeart Trial in End-Stage Heart Failure Read Post »
ResearchWhat Is Hantavirus? Understanding Its Spread, Structure, Symptoms, and Risk... What Is Hantavirus? Understanding Its Spread, Structure, Symptoms, and Risk... Read Post »
ResearchNIH-Funded Study Finds Testosterone May Suppress Glioblastoma Growth in Men NIH-Funded Study Finds Testosterone May Suppress Glioblastoma Growth in Men Read Post »
ResearchNIH-Funded Nature Study Finds Orforglipron Suppresses Pleasure-Driven Eatin... NIH-Funded Nature Study Finds Orforglipron Suppresses Pleasure-Driven Eatin... Read Post »
Clinical TrialsRegeneron Continues Melanoma Development After Phase 3 Trial Miss Regeneron Continues Melanoma Development After Phase 3 Trial Miss Read Post »
New Drug ApprovalFDA Approves Tecentriq as First ctDNA-Guided Therapy for Bladder Cancer FDA Approves Tecentriq as First ctDNA-Guided Therapy for Bladder Cancer Read Post »
New Drug ApprovalMHRA Approves Vyjuvek for Dystrophic Epidermolysis Bullosa MHRA Approves Vyjuvek for Dystrophic Epidermolysis Bullosa Read Post »
New Drug ApprovalFDA Approves Enhertu After Positive DESTINY-Breast Phase III Results FDA Approves Enhertu After Positive DESTINY-Breast Phase III Results Read Post »
GenericsAlteogen Secures Korean Approval for EYZANFY in Retinal Diseases Alteogen Secures Korean Approval for EYZANFY in Retinal Diseases Read Post »
GenericsApotex Launches Generic Ozempic Equivalent Apo-Semaglutide in Canada Apotex Launches Generic Ozempic Equivalent Apo-Semaglutide in Canada Read Post »
GenericsSandoz Wins EU Approval for Bysumlog and Dazparda Biosimilar Insulins Sandoz Wins EU Approval for Bysumlog and Dazparda Biosimilar Insulins Read Post »
Clinical TrialsXPro™ Shows Cognitive and Biomarker Benefits in Phase 2 Alzheimer’s Tri... XPro™ Shows Cognitive and Biomarker Benefits in Phase 2 Alzheimer’s Tri... Read Post »
Clinical TrialsPalvella Reports Phase 2 Data Supporting QTORIN in Rare Vascular Disorder Palvella Reports Phase 2 Data Supporting QTORIN in Rare Vascular Disorder Read Post »
Health TidingsAstellas Secures China NDA Acceptance and Priority Review for IZERVAY in Ge... Astellas Secures China NDA Acceptance and Priority Review for IZERVAY in Ge... Read Post »
Clinical TrialsAstraZeneca’s VOLGA Trial Shows Perioperative Imfinzi Plus Enfortumab Ved... AstraZeneca’s VOLGA Trial Shows Perioperative Imfinzi Plus Enfortumab Ved... Read Post »
Health TidingsAstellas Seeks Japan Approval for PADCEV-Keytruda Perioperative Regimen Astellas Seeks Japan Approval for PADCEV-Keytruda Perioperative Regimen Read Post »
Health TidingsAardvark ARD-101 Program Placed on Full FDA Clinical Hold in Prader-Willi S... Aardvark ARD-101 Program Placed on Full FDA Clinical Hold in Prader-Willi S... Read Post »
Health TidingsNICE Approves AstraZeneca’s Durvalumab for Aggressive Stomach Cancer NICE Approves AstraZeneca’s Durvalumab for Aggressive Stomach Cancer Read Post »
Health Tidings Mergers & AcquisitionsEli Lilly and UNICEF USA Strengthen Childhood NCD Care in LMICs Eli Lilly and UNICEF USA Strengthen Childhood NCD Care in LMICs Read Post »
Health TidingsChugai and Nippon Shinyaku Seek Japan Approval for Gazyva in Nephrotic Synd... Chugai and Nippon Shinyaku Seek Japan Approval for Gazyva in Nephrotic Synd... Read Post »
Health TidingsIpsen Presents Phase II LANTIC Data for Corabotase in Glabellar Lines at SC... Ipsen Presents Phase II LANTIC Data for Corabotase in Glabellar Lines at SC... Read Post »
Clinical TrialsBiogen’s Diranersen Falls Short on Primary Goal Yet Signals a Breakthroug... Biogen’s Diranersen Falls Short on Primary Goal Yet Signals a Breakthroug... Read Post »
Clinical TrialsEyePoint Confirms Favorable Safety Profile for DURAVYU in Phase 3 Wet AMD T... EyePoint Confirms Favorable Safety Profile for DURAVYU in Phase 3 Wet AMD T... Read Post »
Health TidingsFDA Grants Fast Track Designation to XPro1595 for Early Alzheimer’s Disea... FDA Grants Fast Track Designation to XPro1595 for Early Alzheimer’s Disea... Read Post »
Clinical TrialsREGENXBIO Delivers Positive Results for Duchenne Therapy RGX-202 REGENXBIO Delivers Positive Results for Duchenne Therapy RGX-202 Read Post »
Clinical TrialsShionogi Builds a New COVID-19 Defense Line With Positive Phase 3 Ensitrelv... Shionogi Builds a New COVID-19 Defense Line With Positive Phase 3 Ensitrelv... Read Post »
New Drug ApprovalTaiho’s INQOVI With Venetoclax Approved for Patients Unable to Receive In... Taiho’s INQOVI With Venetoclax Approved for Patients Unable to Receive In... Read Post »
New Drug ApprovalBeOne Gains FDA Accelerated Approval for BEQALZI in MCL BeOne Gains FDA Accelerated Approval for BEQALZI in MCL Read Post »
GenericsLupin Receives FDA Approval for Generic Famotidine Injection Lupin Receives FDA Approval for Generic Famotidine Injection Read Post »
Health Tidings Mergers & AcquisitionsEnodia Therapeutics Acquires Sec61-Based Assets from Kezar Life Sciences Enodia Therapeutics Acquires Sec61-Based Assets from Kezar Life Sciences Read Post »
New Drug ApprovalEuropean Commission Approves Pfizer’s HYMPAVZI for Haemophilia Patients European Commission Approves Pfizer’s HYMPAVZI for Haemophilia Patients Read Post »
Health TidingsCoya Therapeutics Secures FDA Fast Track Tag for COYA 302 in ALS Coya Therapeutics Secures FDA Fast Track Tag for COYA 302 in ALS Read Post »
Health TidingsGyre Gains NMPA NDA Acceptance for F351 Liver Fibrosis Therapy Gyre Gains NMPA NDA Acceptance for F351 Liver Fibrosis Therapy Read Post »
Clinical TrialsEncoded Presents Positive POLARIS Data for ETX101 in Dravet Syndrome Encoded Presents Positive POLARIS Data for ETX101 in Dravet Syndrome Read Post »
Clinical TrialsKura Oncology and Kyowa Kirin Report Updated Frontline Data from KOMET-007 ... Kura Oncology and Kyowa Kirin Report Updated Frontline Data from KOMET-007 ... Read Post »
Clinical TrialsNovo Nordisk Reports Up to 21.6% Weight Loss with Oral Wegovy in OASIS 4 An... Novo Nordisk Reports Up to 21.6% Weight Loss with Oral Wegovy in OASIS 4 An... Read Post »
Regulatory & Health PolicyFDA Seeks Public Input on Drug Repurposing Opportunities FDA Seeks Public Input on Drug Repurposing Opportunities Read Post »
